EyePoint (EYPT) announced that Michael Campbell has been appointed Chief Commercial Officer. Campbell will assume responsibility for EyePoint’s commercial strategy and launch readiness for Duravyu, currently in Phase 3 development for wet age-related macular degeneration and diabetic macular edema. Campbell will report directly to Dr. Jay Duker, President and CEO, and will serve on the executive leadership team. Prior to joining EyePoint, Campbell was the Chief Commercial Officer at Opthea
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYPT: